What is your preferred first line treatment approach for a patient with PDL-1 high (>50%) NSCLC presenting with CNS mets?
If a patient is asymptomatic at presentation, how do you incorporate local treatment options (RT/surgery) and when?
Community PollStarted
What factors would prompt you to use chemo+IO combinations vs IO immunotherapy alone?
53 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Karmanos Cancer Institute, Wayne State University
Answered on
The treatment decision and sequencing in patients with brain metastasis from non-oligometastatic NSCLC with high PD-L1 expression and no traditional actionable genomic alterations depend on size and location of brain mets as well as associated symptoms.
Based on data from several prospective and retr...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · University of Colorado Cancer Center
Answered on
Pembrolizumab, if asymptomatic. SBRT in addition, if symptomatic.
Join for free or sign in to see the full answer